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       On the basis of attracting informationconcerning metabolism (e.g., cysteine or gulutathione 
   conjugation), biomimetic reactions using simple SH compounds and enzymes, and sulfur chemistry, 
   numerous functional segments which exihibit good reactivity with SH groups are arranged into two 
   categories; i.e., one which performs electrophilic addition (EA) to an SH group and the other which 
   possesses functional groups causing displacement reaction (DR) with theSH group. With a view to 
   design new SH-alkylating tumor inhibitors the introduction of various EA and DR type functional 
   segments as listed in Tables 1 and 2 into simple compounds would lead to antitumor activity. The 
   enhancement factors on the tumor inhibitory activity, the importance of hydrogen-bonding, lipophilic 
   ester side chains, and bifunctional and multifunctional effects by combination of various functional 
   segments are discussed. Biomimetic model reactions of some tumorinhibitors and related compounds 
   using simple SH-containing compounds and SH enzymes are explained. Studies for the development 
   of the antitumor active diterpenoids of "Enmei-so" (Rabdosia j ponica Hara and R. trichocarpa Kudo) 
   and related plants are described in detail from several points of view. Finally, recent extensive 
   studies on DNA-interacting tumor inhibitors are summarized and the design for a new type of 
   radiosensitizers for cancer radiotherapy is introduced. 
     KEY WORDS: SH-Alkylating tumor inhibitor/ Functional segment/ 
Hydrogen-bonding/ Lipophilic ester side chain/ Bi-
                   functional and multifunctional effect/ SH Enzyme/ 
                   Rabdosia diterpene/ DNA-Interacting tumor inhibitor/ 
                   Hypoxic cell radiosensitizer 
1. INTRODUCTION 
     The study of the naturally occurring and synthetic tumor, inhibitors is of the 
  current interest. Previously, Fujita and co-workers have reported new antitumor 
  active diterpenes which readily react with SH compounds under the mild conditions.' 2) 
  During the course of this study, a review article concerning classification of the 
 functional segments which are reactive to the SH group and tumor inhibitors having 
 potential for interaction with SH enzymes and/or coenzymes was published by Fujita 
  and Nagao.3) In the meantime, we have been interested in development of the 
 tumor inhibitors particularly with the appearance of the antitumor activities which 
 is attributed to the cleavage of cellular DNA or to the perturbation of the DNA repli-
  cation by DNA-drug binding. Thus, we have developed new polyamine-containing 
    * Dedicated to Professor Emeritus Eiichi Fujita on the occasion of his retirement. 
   ** AI V j16, a 1Et: Cancer Drug Research Laboratory, Institute for Chemical Research, Kyoto 
      University, Uji, Kyoto 611. 
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compunds for cancer radiotherapy that would involve the sensitization of hypoxic 
radioresistant cells in tumor  tissues.4,5) In this context we wish to mainly the papers 
concerned with the SH-alkylating and DNA-binding tumor inhibitors. 
                 2. SH-ALKYLATING TUMOR INHIBITORS 
2-1. Design of Active Centers of SH-Alkylating Tumor Inhibitors 
   It is well known that DNA and RNA polymeraseand other biologically important 
enzymes have several SH groups in their molecules.6'7) Compounds containing SH 
group such as glutathione, cysteine, and SH enzymes are significantly enriched in caner 
cells. Therefore, one can readily realize that the particular compounds reacting 
with an SH group may be expected to exhibit an antitumor activity.3) 
   On the basis of various information on in vivo metabolism as well as biomimetic 
       Table 1. Functional Segments Causing Electrophilic Addition(EA) to SH Groupa,b 
 RR       R r--) r....1xx ________.".-...) '.'"'% (CH2)(CHZ)n 
  R~~00o X 0X 0           R 0 
EA-1EA-2 EA-3EA-4EA-5EA-6 
X=H, alkyl,X=H,alkyl,X=NH2,X=NH2, OH, 
alkoxy -alkoxy,OH,- alkoxy, 
                       OHH,Y= OH, H,
alkoxyalkyl,, 
          00alkoxy 







   0.J0/0,kR^R^R XIICN0•-1~Oo—Ao 
EA-1300 R 
X=CHR, NREA-14 EA-15EA-16 EA-17EA-18- 
R 
            R R\~0.R 0RC) r....,/Ar. 
N ,r-)/C=O ("\..r\. O 
C,8(R)H~~OX~~OR 0 Ar~ 
EA-19EA-20 EA-2lEA-22EA-23 EA-24 
                            0.alkylR             N~LN>—R   Cl
liC-                RR 
     EA-25 tEA-26EA-27 EA-28 
              a R=H
, alkyl,aryl. 
b , : Position of addition. 
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           Table 2. Functional Segments CausingDisplacement Reactiona(DR) with SH Group'', a 





X= halogenX=halogen,X= halogen X=halogen Y=halogen, N(Racyloxy Y=OH,N 2, 
alkoxy,aryl 
    Rh\~R~~/1/p 1~0           /OSGl—X 
DR-5 DR-6DR-7 , DR-8 DR-9 
X=CN,-I =0, 
                                                      electron 
withdrawing 
                                                          groups 
         
II^'O(CH2)nof \R(CHZ )a.._.,0R00 Ro i0                       ,,,ILT--.....,...) 
                                                       
/ ----- 0 
DR-10 DR-IIDR -12 DR-13 
                NO2                                                                                    HN —R 
             (~~/~Il/N
NR,J(CH2),, R 
             R 
            as)I'YN.,/~                                                RV-I       (--0--x) (NO2)0/t`NOZ HOSHu 
0 DR-14 DR-I5DR-I6 DR-17 R DR-I8     X=halogen,N2CI-X =0,NH -------------------------------------------- R~N a Including eubetltutlon
, addition - elimination, and elimination-addition. 
DR
]]=H, alkyl, aryl. 
                                          02N t 
             °r~Attacking position of SH group.DR-19 
     reactions with simple SH compounds and some enzymes,8-18)numerous functional 
     segments which react with SH groups are arranged into two categories; i.e., one which 
    involves electrophilic addition (EA) to an SH group and the other which causes 
    displacement reaction (DR) between the suitable leaving groups and the SH group 
    at the a+ carbon atom in the functional segments (see Tables 1 and 2).3) Among 
     some reactive centers in a functional segment, the more "soft" 3+ carbon atom should 
     be attacked slectively by an SH group, because the sulfur atom has generally a large 
     polarizability and "soft base" character.13-13) 
        Thus, either natural or synthetic compounds having such functional segments as 
    shown in Tables 1 and 2 may be expected to exhibit some biological activity (e.g., 
     tumor inhibitory, cytotoxic, antibacterial, antifungal, antiviral, or plant growth inhibi-
    tory activity). The functional segments listed in Tables 1 and 2 seem to be very sug-
     gestive and useful for design of new tumor inhibitors, the search for antitumor active 
    lead compounds from the store of known compounds, and investigation of the mecha- 
                               (134)
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nisms of biological activities. In fact, many naturally occurring and synthesized tumor 
inhibitors possess these functional segments in their  molecules.3,16-22) Of course, 
these functional segments involve only the active centers, therefore the cooperative 
assistance of the activity-enhancement factors or of the hydrophilic factors is very 
important for effective biological activity in vivo. 
2-2. Enhancement Factors on the Tumor Inhibitory Activity 
   1) Hydrogen-Bonding 
   Dehydroailanthinone (1), isolated from Pierrodendron kerstingii by Kupchan and 
co-workers, showed significant antileukemic activity against P-388 in mice. However, 
methylation of the C-1 OH group of 1 resulted in a diminution of cytotoxicity and of 
in vivo antileukemic activity. Plausibly the hydroxyl group enhances the reactivity 
of the conjugated ketone toward biolobical nucleophiles through intramoleculra 
hydrogen-bonding as shown in Fig. 1.23) 
OH 
   HO 0                   • E"
H (CH1C•He1J} 
        1Fig . 1 
   Although cucurbitacin B (2) showed a remarkably high cytotoxicity, its C-16 
acetate, fabacein, showed only a weak activity. The remarkable diminution in 
cytotoxicity suggests that the free hydroxyl group on C-16 may be important for the 
reactivity of the conjugated ketone and the hydrogen-bonding between the C-16 
hydroxyl group and the C-22 ketone could activate the ag-unsaturated ketone toward 
nucleophilic attack by a biological macromolecule as shown in Fig. 2.24) 
Nu 
                                                        H ` OAc 
        •OH 41 
•HO.._OHOAc00~                                 H~.9HHO°
                                                Fig. 2 
   2) Lipophilic Ester Side Chains 
   Gnididin (3), gniditrin (4), and gnidicin (5), diterpenoid esters isolated from 
Gnidia lamprantha by Kupchan and co-workers, showed potent antileukemic activity 
against P-388 leukemia in mice. However, 12-hydroxydaphnetoxin (6), possessing 
no ester moiety at C-12, showed no antileukemic activity. Benzoate ester derivative 
(7) showed potent activity of the same order as the naturally occurring esters.25) 
Gnidilatin 20-palmitate (8) and gnidilatidin 20-palmitate (9) exhibited substantial 
inhibitory activity at optimal doses against P-388 leukemia in mice. Gnidilatin (10) 
showed moderate activity. Gnidiglaucin (11) and gnidilatidin (12) did not show 
inhibitory activity.26) Thus, the ester moiety may serve as a carrier group in process 
concerned with cell penetration or selective molecular complex formation. 
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O•R3: R = COCHLCHCHtCH(CHA•CH, 
•4: R = COCH1CH (CH =CH2)z(CHz)z0H5 
HL • • 5: R m COCH 4CHC&Hs 
.' • H 6: R m H                                                                7: R = COCeHS 
0 HO HzOH 
OR'•_I 
\//\ -\/'./'CH=ai-cH 
H :O 0...H 
                    0 HOORz0 HO •R2 
                                                8: R'=COC•H5; R2=COC15H3.9: R'= COC•HS;RZ=COC,*l.
=COCdHs: Rz=H12: R'=000aH,.Rz=H 
11: R'=COCH:: Rz=H 
             Maytansin (13) and its analogous compounds, novel ansamacrolides from Maytenus 
species,27-30) Putterlickia verrucosa,29,31) and Colubrina texenis,32) are powerful antileukemic 
         agents. Maytansin (13), maytanprine (14), maytanbutine (15), and maytanvaline (16), 
         which possess an ester side chain at C-3 position, showed highly antitumor activity. 
          However, maysine (17), normaysine (18), and maysenine (19), which have no ester 
         group at C-3, did not show activity in vivo and showed about 1/10000 cytotoxicity of 
          maytanside esters such as 16. Maytanacine (20) from P. verrucosaand several semi-
          synthetic esters, 21, 22, and 23, prepared from maytansinol (24), showed antitumor 
          activity comparable to naturally occurring substituted alanyl esters. Maytansinol 
          (24) showed no antitumor activity in vivo.31) Hence, it may be correct that the ester 
          function in the antileukemic maytansinoids may play a key role in vivo system. It is 
          noteworthy that ansamytosin antileukemic antibiotics, novel maytansinoids 25-.27, 
          were obtained from a fermentation broth of Nocardia species by Takeda chemical indus-
       tries group.33)
I' 
                                                    R 1              ^ CI 
               CHs I~0R 
                           CHI./r!,                  CFb/Ii0
        /ICHs • 
                                     dir 
H 
                             CHs CHsO0HCHSC1130HH 
                      13: R=CH317: R=OHS 
                         14: R=cH2cH318: R=H
                          15: R=CH(CH3)zI 013 R                                     16:R=CH:CH (C11)zCHSO ,I 
                                                                                                                   • 04: 
1HIC 
                                     CH30 
            to 
                                   '• 
/ / Hs 
CH3C.1130C.1130 H • 
0 H20: R=COCHs 
                                013 CH30 H21: R=COCH3CH3
                        1922: R=COCH2Br 
                                                                    23: R=COCH=CHCH3
                                                             24: R=H 
                                                    25: R=COCH (CH3) 2 
                                                       26: R=CO (CH2) 2CH3 
                                                       27: R=COCH2CH(CH3) 2
                                                          28: R=000F3 
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   3) Bifunctional or Multifunctional Effect 
   The bifunctional or multifunctional effect due to two or several functional segments 
in the molecule of  tumor inhibitors is essentially important for the enhancement of the 
antileukemic activity. Lee and co-workers demonstrated it by the systematic investi-
gation of the structure-activity relationship among the sesquiterpene lactones and 
related compounds. 
   The comparison of the ED50 values (pg/ml) for the cytotoxicity (against the growth 
of KB tissue culture cells) of helenalin (29) and its chemically modified compounds 
disclosed that both the 2,3 double bond of 29 (ED50=0.10) and the 2,3-epoxide of 
compound 30 (ED50=0.11) gave equally effective cytotoxicity. The 1,2-epoxide of 
compound 31 (ED50=0.53) is five times less active in comparison with 29 and 30. 
The corresponding saturated compound 32 (ED50=3.84) gave a 35-fold decrease in 
activity. Significant cytotoxicity could also be maintained when two potential alkylating 
centers, such as the a(3-unsaturated carbonyl system in the conjugated cyclopentenone 
and the a-methylene r-lactone segments of helenalin (29), were converted to the 
a19-epoxy carbonyl system, although the diepoxide 33 (ED50=0.50) was five times less 
active in comparison with 29. Compound 34 (ED50> 40.00) was more than an 80-fold 
diminution in cytotoxicity in comparison with 33.34) 
        I"HI 
          40'y0                 oO        OHOH 
293031 
       H;~HIH I 
o I •                                      0
0 
        OH ,a OHOH 
     323334 
   The diesters 35-48 were assayed for their in vivo antileukemic activity against 
P-388 lymphocytic leukemia in mice by Lee and his group. Examination of the in 
vivo data demonstrated that at 8 (mg/kg)/day compounds 35 and 36 afforded a higher 
percent T/C value (35: T/C =195 %, 36: T/C=173 %) than 29 (T/C=162 %), whereas 
at 15 mg/kg compound 37 extended the life expectancy of the mice two fold (T/C= 
261%) compared to compound 29 (T/C=123 %). At 25 mg/kg, compound 38 
afforded a percent T/C=178, compared to 29 with a percent T/C=127. These data 
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parent alcohol helenalin (29) at specific doses and several alkylating centers in the 
particular ester delivatives may cooperatively affect on their activities.35) 
   Bisbrusatolyl esters 39-43 showed equal or more potent activity against a 
quassinoid-sensitive strain of P-388 lymphocytic leukemia than brusatol (44) at 
0. 6 mg/kg (compare T/C% of 272, 217, 176, 176, and 143 for 39, 40, 41, 42, and 
43, respectively, to 149 for 44) .36, 37) 
                           OH 
             HOCOOCH3t>}IAtHO COOCHH3 
       OOCO 
H0~•'OCO<            0O00 H }i H H\





43: n 8 
                                OH 
                      H0COOCH3 
             0~:,CO 
                                     H 
         HO0 0                       H 
H 
                               44 
   Tetrandrine (45), a bisbenzylisoquinoline alkaloid from Cyclea peltata Diels,38) 
and vincristine (46) and vinblastine (47), dimeric indole alkaloids,19) are known to 
be clinically useful antitumor agents. Activities of these alkaloids may be explainable 
by the effect of bifunctional segments. 
                                                                            R1 
H COZCH3 
OCH3 CHO 
CH3 N OCH3 0CH3N 
H                                                                  'H
®OCH3 o               ®CH30 • R30 OAC 
      45co3 CH3 
R 1 R3 R3 
47:OH H CH,. 
46: OH H CHO 
2-3. Biomimetic Reactions of Tumor Inhibitors and Related Compounds 
     with SH Enzymes and Coenzyme and Their Model Compounds 
    Informations obtained from the biomimetic reactions of tumor inhibitors and 
related compounds with simple SH compounds, SH enzymes, and glutathione (co-
                            ( 138 )
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enzyme) can be useful for the better understanding of their active mechanisms and 
for design of new SH-alkylating tumor inhibitors. 
   Treatment of a-methylene lactone tumor inhibitors, vernolepin 48,  elephantopin 
49, and eupatundin 50, with aqueous solution of L-cysteine at pH 7.4 afforded each 
corresponding cysteine adduct 51, 52, and 53, respectively.39) 
                                         0 
                    •0> ---‹HO H 0 
   OH                                           Or) 
                                                       HO 
             0 t{ 
    48•00           49
50 
                                           \\
/ 
                      Sr           0 H • o.0•,~....HO                                                            0
          /NH3—co;H3N0 ,0S1 rH3N~COz COzHACOz 
    515253 
   Inhibition of an SH enzyme, phosphofructokinase, by taxodione (54), taxodone 
(55), vernolepin (48), euparotin acetate (56), eupacunin (57), and some standard 
inhibitory reagents 58-.60 against SH enzymes was investigated by Kupchan and 
his group in the absence and presence of the substrates (fructose-6-phosphate and 
ATP). Addition of only 1.6 mol of taxodione (54) per protomer of the enzyme 
diminished its enzyme activity by 50%. Taxodone (55) inhibited 50% at a relative 
concentration of 32. Euparotin acetate (56), eupacnin (57), and vernolepin (48) 
inhibited 50% at relative concentrations of 1000 to 2000. Taxodone (55) exhibited 
same order inhibition as that of N-ethylmaleimide (58) and Ellman's reagent (59). 
However, ap-unsaturated lactones (48, 56, and 57) were only about ten times more 
active in comparison with iodoacetamide (60). The substrates, fructose-6-phosphate 
and ATP, were shown to protect the enzyme from each of the inhibitors.40) Thus, 
the quinone methide segment seems to be more reactive to the SH groups of enzymes 
than the a-methylene lactone segment. 
'0CH5C•z H9 0 
   OS•                  iiity.     •,.H .eelH•---0 0OHI0 
545556 •57 
                          o 
C2H5—N II O25—NO2 H2NCCH27                        
IIV                                                           il 0 CO
2HCO2H 
     585960 
   Inactivation of glycogen synthase by vernolepin (48) was examined by Kupchan 
group.41) Reaction with 3 mol of radioactive vernolepin per 90000-dalton subunit 
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            caused complete loss of activity. The concurrent disappearance of three titrable SH 
           groups (out of six) indicates that thioether formation is the major model of binding to 
             the protein.41) 
2-Crotonyloxymethyl-4,5,6-trihydroxycyclohex-1-en-3-one (61), isolated from a 
            culture broth of Streptomyces griseosporeus as a component of glyoxalaseI inhibitor, ex-
           hibited tumor inhibitory activities against HeLa cells in vitro, and also against Ehrlich 
            ascites carcinoma and L-1210 cells inoculated in mice.42) As shown in Chart 1, the 
            crotonyloxy group of 61 was readily displaced by 2-hydroxyethanethiolor p-bromo-
           benzenethiol to afford the SH adduct, 62 or 63, while the hydrolyzed alcohol 64 did 
            not react with thiols. These biomimetic reactions may provide a rationalization for 
            the antitumor activities of 61. Compounds 62, 63, and 64 did not showany biological 
            activity as expected 4) 
                                                          H\ /CHs 
                                                                      0 c=c 
                             ?-CH2CH2-OHq'-C/\I.,r()er 
          CH
-~/                     Lo HSOBrO
                                           S rtrHO•OHPhosphoteHOOHPhosphate~~ ''OH                                                       buffer soln.buffer soln. 6
H (pH7.4)OH (pH7.4)OH 
                   62 37°C61 37°C63
(xi  NHCI 
reflux 
                                                               OH
                                                                        CH2 
                                                 64
                                       HO'OH 
OH 
                                                 Chart 1 
               The reactions ofjatrophone (65), an antileukemic macrocyclic diterpenoid isolated 
           from Jatropha gossypiifolia by Kupchan group, with 1-propanethiol in a borate buffer 
           solution gave the SH adduct 66 (Chart 2).4) Jatrophone (65) was shown to react 
           with SH groups on proteins such as bovine serum albumin and DNA-dependent RNA 
             polymerase from Escherichia coli.45) 
00                                  ..siiie       ...MP rSH 
                                                           buffersoln.(PH9.2)H 
—THF 0 SCH2CH2CH3 
       6566 
                                              Chart 2 
               Helinalin (29) was homogenized with reduced glutathione in deuterated water 
            and the formation of glutathione adduct 67 was confirmed by its NMR spectrum.46) 
            Helinalin was shown to be an effective inhibitor of DNA polymerase activity of Ehrlich 
            ascites cells in vivo.47) Presumably, the DNA polymerase alpha and gamma enzymes 
            contain exposed SH groups which can be alkylated. 
               In vitro DNA polymerase activity of Ehrlich ascites cells was inhibited drastically 
(>50%) by helinalin (29), compounds 30, 35 and 68-72 at 0.75 pmole. In vitro 
           thymidylate synthetase activity was inhibited (at least 40%) by compounds 29 and 
(140)
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35 and also inhibited (at least 30%) by 71 and 73, respectively at 0.75  4amole. 
Thymidylate synthetase was reported to be a sulfhydryl-bearing enzyme.48) 
                                 ~ 011 
                              oCOOC H,




     67 CH,0 
COOH' 0 
                                                 0 
                                                    0
     0069 
         ,oJY•JJ 
                     HO 60 (CH.,OH 
00 
_          70CH 2OH 
    CH,CH2O0 
       I0I71                        ..OJr CH,000,` 
                    ~''J~1      0 72I0~CH2OH
H \/   CH2OH 
                      73 
   Other similar enzyme inhibitions using various tumor inhibitors were reported 
by Lee group.49-52p 
2-4. Studies on the Rabdosia Tumor Inhibitory Diterpenoids 
   Labiatae species have been used as medicinal plants for the treatment of cancer 
in various countries from ancient times.53) Rabdosia japonica HARA (Labiatae) and 
R. trichocarpa KUDO (Labiatae) have also been used as the home remedy in Japan. 
However, their biological activities have not yet been clarified. Hence, Fujita and 
Nagao investigated in detail the antitumor and antibacterial activity on some 
available diterpenoids and related compounds), 2, 54, 55) 
   Oridonin (74) (10 mg/kg, T/C=215%) and lasiokaurin (75) (10 mg/kg, T/C = 
217 %) showed a fairly high activity against Ehrlich ascites carcinoma inoculated in 
mice. Enmein (76) (25 mg/kg, T/C=166%), enmein-3-acetate (77) (40 mg/kg, 
T/C=156 %), compound 78 (40 mg/kg, T/C=165 %), and oridonin 14-deoxy-
derivative 79 (20 mg/kg, T/C= 161 %) showed activity at the higher dose than that 
of oridonin (74) . Oridonin dihydro-derivative 80, butanethiol adduct 81, dihydro 
enmein (82), and trichokaurin (83), however, did not show any activity. Thus, the 
a-methylene-cyclopentanone segment was shown to be an important active center of 
the tumor inhibitory Rabdosia diterpens.l, 2) 
   Many antitumor sesquiterpenes possessing the a-methylene-r-lactone segment as 
an active center in the molecule have been reported, but the antitumor natural products 
(141)
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having a-methylene-cyclopentanone segment had not been known except for sar-
comycin (84) .es, 57) 
          WO 20 uuoR'g, 
                  Hulk 120 -I          '10•R2
O 
               1:4OHO®76: R'=OH, R'=H, R'=CH,                6:1II;77 : R'=OAc, R'=H, R'=CH, 
74: R'=H, R'=0HR' p H78: R'=H, R'=OH, R'=CH, 
                 75: R'=Ac, R'=OH82: R'=OH,R'=H,R'=aCH,,ftH
                  79: R' = R'=H 




        tHOH~AcOH840 
        80:R=H83 
                 81: R=S(CH,),CH3 
   Intensity of the activity and its relation with structure are also investigated. Since 
oridonin (74) and lasiokaurin (75) showed almost the same intensity of the activity, the 
OH group at C-1 has no direct effect for the activity. An important role of the 
OH group at C-6 is clarified by the following fact. The activities of enmein (76), 
enmein-3-acetate (77), and compound 78 are 1/4 or lesser in comparison with that 
of oridonin (74). The hydrogen-bonding between the carbonyl group at C-15 
and the OH group at C-6 in oridonin (74) has been confirmed by its IR, UV, and 
NMR spectra. Hence, the C-17 atom is polarized to o+ and its reactivity with 
nucleophile must be increased (Fig. 3). In fact, it is supported by the lower chemical 
shifts of C-17 methylene protons of oridonin (74) than those of enmein (76), enmein-
3-acetate (77), and compound 78, that the electron density of C-17 of oridonin is 
lower than those of 76, 77, and 78.2) 
HO ~~ ^.Nu 
0—H' 
                                               Fig. 3
   In order to validate the argument mentioned above, we planned the examination 
of antitumor activity of C-6 acyloxyl derivatives of oridonin (74). We investigated 
preparation of the desired acyl derivatives of oridonin. After several attempts, we 
found an efficient method for selective acylation of the OH groups of 74. On treatment 
with excess Ac2O and a catalytic amount of BF3 • Et20 under ice-cooling, oridonin 
(74) was converted to the 6-acetate 85 in 25.1 % yield and the diacetate 86 in 
63.8% yield. Oridonin (74) was treated with the more bulky dodecanoic anhydride 
in the presence of a catalytic amount of BF3 • Et20 at room temperature to give only the 
6-dodecanoate 87 in 83 % yield. On the other hand, oridonin (74) was reacted with 
several acyl chlorides in the presence of Et3N to afford each corresponding 14-0-acyl 
derivative 88~95 exclusively (Chart 3).58) 
(142)
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  H9 HOHQ 1~_C RCOCIOCOR                                                         ~
         fROHC. O•OHOHCHCI,/~OH      '0 -14 
R'=RCO , R'=H7488 - 95 
R'=R'=RCO 
85 - 87 
                                             88: R'=H, R'=COPh 
                                                89: R'=H, R'=COCH=CHPh                               H9
90:R'=H,R'=COCH,                      n91:R'=H ,R'=COC,H„ 
       ,~                                         OR92: R'=H, •93:R'=H ,R'=COC,,H„                                 H
, R'OH 94: R'=H, R.—COC„H,, 
                                                95: R'=H,R'=COC,,H„
                                                85: R'=Ac,R'=H                                                 6
: R'=R'=Ac 
                                                87:R'=COC„H,,,,R'=H
                               Chart 3 
   Thus, 6-0-acyl derivatives 85,-87 were submitted to the antitumor test against 
Ehrlich ascites carcinoma inoculated in mice. All of the tested compounds were 
found to be inactive at the dose of 5 mg/kg and 10 mg/kg, at which doses oridonin (74) 
did exhibit activity.59) 
   It was again supported by the 13C—NMR analysis of oridonin (74) and the 6-0-acyl 
derivatives (85 and 87) that the hydrogen-bonding between the carbonyl group at C-15 
and the OH group at C-6 must result in a+ nature at the C-15 and C-17 atoms in 
oridonin (Table 3) . The increased soft electrophilicity of the C-17 atom would 
then make the addition of e.g. the SH group of enzymes in the tumor cells easier. 
Therefore, the ability of oridonin (74) to act as an alkylating agent is enhanced 
(Fig. 4).59) 
        Table 3. The 15C-NMR Chemical Shiftsa> of the C-15, C-16, and C-17 Atoms 
               in Oridonin (74) and the 6-Acyl Derivatives 85 and 87
                              Oridonin-
                    Oridonin 6-acyl derivative Values of 
                    74 85 87 d S (74-85) and d8 (74-87) 
PPm PPm PPm PPmPPm 
H H 
\/ C
,7 119.0 115.2 115.2 +3.8 +3.8 
                     n 
          —C, 6 153.0 153.5 153.6—0.5—0.6 
0=615 209.0 200.8 200.9+8.2 +8.1 
       a) Taken in d,-pyridine; ppm from TMS as an internal standard. 
                           HH 
                           SC= I'—C0--- H—O 
                 17 16 156 
                             Fig. 4 
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   The antileukemic test of a series of oridonin 14-0-acyl derivatives 88-95 was 
carried out in order to clarify the significant effect of the ester side chains on the tumor 
inhibitory activity of oridonin. In compounds 90,-95, the activity was found to be 
increased with increase of the acyl carbon chain length. The activity of 14-0-
dodecanoyl 93, tetradecanoyl 94, and hexadecanoyl 95 derivatives was shown to 
be stronger than that of oridonin (74), although 94 and 95 exhibited some toxicity. 
The benzoyl derivative 88 was shown to have the same order of acitivy as 74, while the 
cinnamoyl derivative 89 had no activity. The derivatives 91 and 92 were shown 
to have slightly stronger activity at a dose of 5 mg/kg in mice than oridonin (74). 
The esters with higher fatty acids, 93—.95, showed stronger activity than those with 
lower fatty acids, 90-92, and also than oridonin (74) it self. The observation that 
there was an increase in the activity with the increase in carbon chain length of 
the acyl groups is interesting. They suggest that the activity increase is in proportion 
to the lipophilicity of the oridonin derivatives.59) Thus, the ester side chain in 
oridonin 14-0-acyl derivatives may play a carrier role in the process(es) related to 
the penetration into cells. 
   Biomimetic reactions of oridonin (74) and enmein (76) were investigated in 
detail using adenosine (96) and cytidine (97), as the nucleic acid model compounds, 
and four kinds of alkane thiols, L-cysteine, L-lysine, and L-serine, as the enzyme model 
compounds.2) 
   Oridonin (74) did not react with adenosine (96) and cytidine (97), and was re-
covered. The reactions of oridonin (74) with the SH enzyme model compounds 
readily proceeded under mild conditions to give alkane thiol adducts (81, 98, 99, 
and 100). The reaction with L-cysteine also took place smoothly to yield adduct 
101 quantitatively (Chart 4). Enmein (76) also easily gave adduct 102 by the reaction 
with 1-butanethiol. This process is shown in Chart 5. Interestingly, it was observed 
that oridonin (74) reacts with 1-butanethiol with much faster rate than that with enmein 
(76) in the competitive reaction in one flask which was followed by tic analysis. The 
reactions of oridonin with L-lysine and L-serine, however, did not take place. Such 
easy addition reactions of thiols as described above without any catalysts are rationally 
explainable as the reactions of "soft" acids with "soft" bases.13-15) Thus, the selective 
reactions of the a-methylene-cyclopentanone systems with only the SH group of 
enzyme containing many other nucleophilic groups (e.g., —OH, —NH2, —COOH, 
etc.) can be rationalized by the "Hard Soft Acids Bases" principle13,15) and experi-
mentally supported by our biomimetic reaction. 
   It was also confirmed by Anke that DNA synthesis was 74% inhibited by 10 pg/ml 
of oridonin (74) and 91 % inhibited by 10 pg/ml of enmein (76) in a test system using 
cells of the ascitic form of Ehrlich carcinoma and the RNA and protein syntheses were 
somewhat less affected. 
   A considerable antitumor activity of oridonin (74) (18 mg/kg, T/C=131 %), 
enmein (76) (25 mg/kg, T/C=131 %), enmein-3-acetate (77) (10 mg/kg, T/C=124%), 
nodosin (103), and shikoccin (104) (15 mg/kg, T/C=123%) was recognized against 
P388 lymphocytic leukemia inoculated into mice. Thiol adducts 98, 105, and 106 
derived from the diterpenes 74, 76, and 104, respectively, did not exhibit any activity. 
(144)
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Therefore, the a-methylene-cyclopentanone segment must be regarded as the important 
active center of the activity against P388 lymphocytic leukemia, as in the case of 
activity against Ehrlich ascites carcinoma.so) 
      4H
0                ...bOH,•4, Ac0 %H OH                                           
. UH 
             103104 
0 ,—SEt 
0S O BT 
                                             H 
                  HO,,lAc•,..OH                           ~H 
           105106 
   In the related study on design for new SH-alkylating tumor inhibitors, we 
developed a new method for the synthesis of a-methylene-cyclopentanone segment 
utilizing a new bissulfenylation reagent, methyl 2-nitrophenyl disulfide (MNPDS) 
(107). A proposed transition state 108 for sulfenylation and the synthetic procedure 
(145)
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of the model compounds 109 and 110 having a-methylene-cyclopentanone segment 
are illustrated in Chart 6.55,61) 
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   The recent advances in the field of Rabdosia antitumor diterpenoids are well 
reviewed by Fujita and Node,62) and Fuji63) independently. 
               3. DNA-INTERACTING TUMOR INHIBITORS 
3--1. DNA-Binding Compounds 
   Some particular antitumor agents such as actinomycin D (111), adriamycin (112), 
daunomycin (113), ellipticine (114), nogalamycin (115), bleomycins (116), and echino-
mycin (117) interact with DNA by intercalation between two adjacent base pairs.20,22) 
The mutual relation between DNA-binding (e.g., intercalation) and antitumor activity 
is not clear. However, the molecular design and synthesis of DNA-binding com-
pounds with high affinity are useful not only for the development of new powerful 
anti-cancer drugs but also for the supply of probes for the DNA structure and function 
studies.64) 
   Actinomycin D (111) has been known for its interaction with DNA, which causes 
a specific inhibition of RNA polymerase, seems to be responsible for its antitumor 
activity. 20, 65) Two peptide rings of actinomycin D (111) are located in the minor 
(146)
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groove of DNA when the flat ring moiety of 111 is intercalated.66) Actinomycin D 
(111) exhibited specific intercalation between G—C base pairs,67) and Sobe1168) postu-
lated that this is due to specific hydrogen-bonding between the peptide ring of 111 
and guanine on the basis of X-ray crystallographic analysis66) of actinomycine-
nucleotide crystals. 
The antibiotic adriamycin (112) and daunomycin (113) are highly cytotoxic 
substances isolated from .a cultured broth of Streptomyces peucetius.69,70) Adriamycin 
(112) exhibited very wide spectrum of antileukemic activity and displayed considerable 
effects against various solid tumors.71) The in vivo binding of daunomycin (113) and 
its analogs to DNA was extensively investigated22,72) and the spectroscopic methods 
were efficiently employed. For example, the 480 nm visible absorption maximum of 
113 was decreased on addition of DNA and was shifted to longer wavelength.73, 74) 
The fluorescence of the anthraquinone chromophore in the anthracycline antibiotics 
was quenched when binding to DNA took place.73, 75) A progressive increase in the 
relative viscosity of DNA was produced upon binding of daunomycin (113),73,74,76) 
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   which was analogous to that produced by other intercalating compounds. 
       Ellipticine (114) and its derivatives showed antileukemic activity against L-1210 
   lymphocytic leukemia in mice.77) This flat molecule compound 114 strongly binds,    b
y intercalation, to helical DNA.78,79) The DNA-binding property of various 
   ellipticine derivatives was investigated in an attempt to correlate DNA affinity with 
   antitumor activity.80) 
      Bleomycins (BLMs) (116), isolated as the Cu(II) complexes from a culture of 
Streptomyces verticillus,81, s2) are clinically used in the treatment of squamous cell 
   carcinoma and malignant lymphoma.83) Cleavage of cellular DNA by BLM seems 
   to be responsible for the antitumor activity.84) Fluorescence and 1H—NMR spectral 
   data indicated that BLM binds preferentially to the guanine base of DNA with its 
   bisthiazole moiety.84) The terminal amine moiety of BLM may play an electrostatic 
' binding role to DNA. Interestingly, BLM promoted cleavage at G—T and G—C 
   sequences of DNA in the presence of ferrous ion and molecular oxygen.84) 
       Echinomycin (117), a naturally occurring antitumor active antibiotic, consists 
           CH3CH3. 
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  of two planar quinoxaline moieties connected by an octapeptide  bridge.35, 86) Waring 
  and co-workers reported echinomycin (117) and its analogs (triostin A and des-N-
  tetramethyltriostin A) to bind to various naturally occurring and synthesized DNA 
  by a fassion involving bis-intercalation of both quinoxaline chromophores common 
  to the antibiotics.87-90) Conformational studies of echinomycine (117) and triostin 
  A are reported by Williams group.91,92) 
     Other DNA-binding compounds are listed in Chart 7.64, 93, 94) These are chloro-
 quine (118), quinacrine (119), 9-aminoacridine (120), proflavine (121), ethidium 
 bromide (122), miracil D (123), methidiumpropyl-EDTA (124),95) distamycine-EDTA 
(125),96) spermine diacridine (126),97) and bis (methidium) spermine (127).98) 
     The particular compounds (124 and 125) were designed by Dervan for cleavage 
  of double helical DNA in the presence of ferrous ion and oxygen. Spermine-containing 
  compounds (126 and 127) proved to be powerful bis-intercalators. 
     On the basis of the suggestive information obtained from the bioorganic chemistry 
  of the DNA-binding compounds, we newly designed several hypoxic cell sensitizers4, 5) 
  in antitumor radiotherapy, which is reviewed in the following paragraph. 
  3-2. Design of New Hypoxic Cell Radiosensitizers 
     Considerable efforts have been made to develop effective compounds for cancer 
  radiotherapy that would involve the sensitization of hypoxic radioresistant cells in 
  tumor tissues. Among them, misonidazole (128) has been known to be an efficient 
  radiosensitizer for hypoxic cells. However, due to its neurotoxicity, its clinical 
  applicability at doses sufficient to produce optimum sensitization limited. 
     Thus, we developed a new type of hypoxic cell radiosensitizers: FNT-1 (129), 
 -2 (130), -3 (131), -4 (132) and —SS-1 (133).4,5) 
     These compounds were designed on the basis of the following reson and infor-
  mation. a) Chemistry of polyamine-containing compounds is familiar to us.99-102) 
 b) The biogene-polyamines [spermidine (134) and spermine (135)] exhibit remarkable 
  charge-charge affinity to the phosphate moiety of the nucleic aicd.97.98,103) c) Some 
  aromatic compounds bind to nucleic acids by intercalation, i.e., the insertion of a flat 
  molecule between the base pairs of a double helix by charge-transfer complex.104) 
  d) Most excellent hypoxic cell sensitizers possess one or two nitro group(s) as the 
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electron-accepting group.1.05, 106)Thus, a speculative intercalator, the4-nitro- or 
3,5-dinitro-benzoyl group was linked to the polyamines, spermidine (134) and spermine 
(135). The whole of the molecular design of these compounds is shown in Fig. 5. 
    Synthesis of FNT-series compounds 129,-133 was efficiently done utilizing a 
highly chemoselective acylating reagent, 3-acy1-1,3-thiazolidine-2-thione (Charts 8 
and 9).101) 
   A radiosensitizing effect of FNT-series compounds on hypoxic cells (HeLa S3 
cells) in vitro was investigated according to the method which was previously reported 
by Mori group.107) Enhancement ratios (ER) of the sensitization of hypoxic HeLa 
S3 cells irradiated in vitro at room temperature were determined for each compound 
over a range of concentrations. The ER was obtained from the Do ratio in the 
absence and presence of the radiosensitizer. However, the maximum concentration 
was limited by the solubility of the compounds. Figure 6 shows the concentration 
dependance of the ER for each compound; the ER for misonidazole (128) is also 
presented for comparison. All curves show an increase in the ER with the increasing 
concentration of compounds, and it is obvious that FNT series compounds are more 
effective than misonidazole (128) (Table 4). FNT-1 (129) and FNT-3 (131) es-
pecially were found to have good sensitizing effects; 1 mM both compounds have 
about 1.6 times sensitizing effect of misonidazole (128). 
    Half-wave reduction potentials (E112) were measured with a Yanaco P-1000 
polarographic analyser using a dropping mercury electrode and standard calomel 
electrode (SCE). Values for the reduction potential were obtained with a Tast 
polarograph. A higher electron-affinity was observed with FNT-1-3 (129: E112= 
-350 mV, 130: —330 mV, and 131: —270 and —380 mV) with that (-395 mV) 
of misonidazole.5) 
    Since spermine and spermidine themselves do not show any sensitization, it is 
reasonable that the radiosensitizing abilities of FNT-series compounds are mainly 
due to the nitrobenzoyl group in their molecules. FNT-series compounds carry 
ionizable basic groups and, as shown by Adams,105) basic nitro aromatic compounds 
are unusually effective radiosensitizers. In addition, these compounds are more 
electron-affinic than misonidazole (128), and therefore more effective in radiosensi-
tizing under the hypoxic conditions than misonidazole (128). 
(150)
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     Table 4. Sensitizer Enhancement Ratios 
   CompoundConcentration ER                 (mM) 
  FNT-10.11.18  3.0 
           1.02.10 G FNT-I • FNT-2 N
NO2N                                             0 FNT-3 
   FNT-20.11.00 o 2.5 ^ FNT-4 CH:CH(OH)CH20 3                                                        •bV FNT-SS-I 0 mlsonidazole
             1.01.45 




1.01.22 I•ogO 'o 
0.1110 
FNT—SS-10.11.20                                                                               Concentration (mM)                                                                                 Fig. 6 
             1.01.85 
   Misonidazole 0.11.05 
             1.01.32 
    Recently, we have found an interesting experimental result in the interaction 
between the FNT-series compounds and NDA, which will be reported very soon,108) 
                           CONCLUSION 
   We reviewed on the design and study of new tumor inhibitors having SH-alkylating 
function and DNA-binding function. From the foregoing discussions, we would 
offer some variable suggestions about a strategy for the development of new tumor 
inhibitors. Thus, for instance, the following process may be served : (1) search for 
compounds including SH-alkylating segment(s) among known compounds; (2) synthesis 
of the lead compounds possessing SH-alkylating segment(s) and/or DNA-binding 
planer segment(s) ; (3) chemical modification of the lead compounds on the basis of 
activity-enhancement factors (e.g., hydrogen-bonding, lipophilic ester side chains, 
and bifunctional or multifunctional effect) ; (4) introduction of hydrophilic moiety 
into the lead compounds for diminution of the toxicity; (5) trying biomimetic reactions 
with simple compounds including an SH group or with DNA; (6) biological testing. 
We eagerly hope this strategy to be utilized as an efficient guide for the development 
of more potent and less toxic cancer drugs. 
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